425: InMed Pharmaceuticals Reports FY26 Results, Merger Progress

InMed Pharmaceuticals reported its fiscal year 2026 financial results, highlighting a net loss of $12.9 million and providing an update on its proposed merger with Mentari Therapeutics, which includes significant pre-closing financing.

Summary

• InMed Pharmaceuticals reported a net loss of $12.9 million for the fiscal year ended June 30, 2026, an increase from the $8.2 million net loss in the prior fiscal year.
• Research and development expenses rose to $3.0 million from $2.8 million, and general and administrative expenses increased to $6.7 million from $5.4 million.
• The company is proceeding with its proposed merger with Mentari Therapeutics, Inc., with the combined entity expected to focus on migraine prevention therapies.
• Mentari has secured approximately $490 million in aggregate pre-closing financing, which is expected to extend the combined company's cash runway into 2029.
• InMed's legacy pharmaceutical programs (INM-901, INM-089, INM-755) are to be managed via a Contingent Value Rights (CVR) structure for legacy InMed shareholders.
• BayMedica, LLC, a wholly owned subsidiary, has ceased operations and its results are presented as discontinued operations, with sales of $3.2 million in FY26.
• As of June 30, 2026, InMed had $2.2 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the significant financing secured for the combined entity and the strategic merger, which offers a path forward. However, the increased net loss and the discontinuation of BayMedica operations temper the overall sentiment.

Positives

• Significant pre-closing financing of approximately $490 million secured for the combined company post-merger with Mentari Therapeutics.
• The merger with Mentari Therapeutics is progressing, with a focus on advancing migraine prevention therapies.
• The expanded financing is expected to provide a cash runway for the combined company into 2029, supporting clinical development.
• InMed is pursuing strategic opportunities for its legacy pharmaceutical programs (INM-901, INM-089, INM-755) through a CVR structure.
• A pre-Investigational New Drug (IND) meeting with the FDA for the INM-901 program was conducted, with feedback being integrated into development plans.

Negatives

• Net loss increased to $12.9 million for fiscal year 2026 from $8.2 million in fiscal year 2025.
• Research and development expenses increased to $3.0 million from $2.8 million.
• General and administrative expenses increased to $6.7 million from $5.4 million, partly due to increased corporate legal expenses.
• BayMedica, LLC, a subsidiary, has discontinued operations, with its sales decreasing to $3.2 million in FY26 from $5.0 million in FY25.
• Cash, cash equivalents, and short-term investments significantly decreased to $2.2 million as of June 30, 2026, from $10.7 million as of June 30, 2025.

Risks

• The merger with Mentari Therapeutics may not be completed on the anticipated timeline or at all.
• Failure to obtain required shareholder and stockholder approvals or satisfy other closing conditions for the merger.
• Risks related to the redomestication, reverse stock split, and Nasdaq continued-listing requirements.
• Risks inherent in preclinical and clinical development, regulatory review, and commercialization of product candidates.
• Potential future monetization of legacy InMed programs (INM-901, INM-089, INM-755) may not be successful.
• The effectiveness of the Form S-4 registration statement is a condition for closing the merger.

Future Outlook

The combined company, post-merger with Mentari Therapeutics, is expected to focus on advancing Mentari's pipeline of migraine prevention therapies. The pre-closing financing of approximately $490 million is anticipated to extend the combined company's cash runway into 2029, supporting Phase 2a readouts for Mentari's lead programs and broader pipeline development. Legacy InMed shareholders will receive Contingent Value Rights (CVRs) related to the potential future monetization of InMed's pharmaceutical programs.

Management Comments

• "This has been an important year for InMed as we position InMed for its next phase through the proposed merger with Mentari Therapeutics, Inc.," commented Eric A. Adams, InMed President and CEO.
• "The additional $200 million private placement announced by Mentari brings the expected aggregate pre-closing financing to approximately $490 million and further strengthens the combined company as we work toward completing the transaction by the end of the calendar year 2026."
• "In parallel, we remain focused on maximizing the potential value of our legacy pharmaceutical programs for InMed shareholders through a Contingent Value Rights (CVR) structure, including pursuing strategic opportunities for INM-901, INM-089 and INM-755."

Industry Context

StockSavvy.ai notes that the pharmaceutical industry continues to see consolidation, with companies seeking to leverage pipelines and financing to advance drug development. The focus on migraine prevention therapies aligns with a growing market segment addressing significant unmet medical needs. The substantial financing secured by Mentari is a positive indicator in a challenging funding environment for biotechs.

Stakeholder Impact

• Shareholders: Legacy InMed shareholders will receive CVRs for potential future monetization of InMed's pharmaceutical programs. They will also be subject to shareholder approval for the merger and potential dilution from future financing rounds.
• Employees: The merger and focus on Mentari's pipeline may lead to changes in organizational structure and roles.
• Creditors: The company's reduced cash position and increased net loss could impact its ability to meet financial obligations if future financing or operational improvements are not successful.

Next Steps

• Complete the merger with Mentari Therapeutics by the end of calendar year 2026.
• Obtain effectiveness of the Form S-4 registration statement.
• Mail definitive proxy statement/prospectus and management information circular to shareholders.
• Secure necessary shareholder and stockholder approvals for the merger.
• Advance Mentari's pipeline of migraine prevention therapies.
• Pursue strategic opportunities for legacy InMed programs (INM-901, INM-089, INM-755) via CVR structure.
• Integrate FDA feedback into drug development planning for INM-901.

Key Dates

Recommendation

The proposed merger with Mentari Therapeutics and the substantial financing provide a clear strategic direction and financial runway, which are positive. However, the increased net loss, significant cash burn, and the inherent risks associated with drug development and merger completion warrant a cautious approach. A 'hold' recommendation reflects the balance between the potential upside of the combined entity and the current financial performance and execution risks.

Keywords

Merger, Mentari Therapeutics, Migraine Prevention, Pharmaceutical Development, Clinical Trials, Financing, Drug Candidates, Corporate Update